• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Aurinia Pharmaceuticals Inc (Amendment)

    3/20/24 5:23:55 PM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AUPH alert in real time by email
    SC 13D/A 1 tm249351d1_sc13da.htm SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    SCHEDULE 13D 

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

    §240.13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13D-2(a)

     

    Under the Securities Exchange Act of 1934 

     

    (Amendment No. 15)

     

     

     

    Aurinia Pharmaceuticals Inc.

    (Name of Issuer)

     

    Common Shares, no par value

    (Title of Class of Securities)

     

    05156V102

    (CUSIP Number)

     

    ILJIN SNT Co., Ltd.

    (Dohwa-dong), 45 Maop-daero, Mapo-gu

    Seoul, Korea 121-716

    Attention: Young Hwa Kim

    +82-2-707-9137

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    March 20, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 05156V102

     

     

     

     

    1.

     

     

    Name of Reporting Person
    I.R.S. Identification No. of above person (entities only) (voluntary)

     

    ILJIN SNT Co., Ltd. 

     

     

     

    2.

     

     

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) x

     

     

     

    3.

     

     

    SEC Use Only

     

     

     

     

     

    4.

     

     

    Source of Funds (See Instructions)

     
    Not Applicable
     

     

     

     

    5.

     

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)  ¨

     

     

     

     

     

    6.

     

     

    Citizenship or Place of Organization

     
    South Korea
     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    7.

     

     

    Sole Voting Power

     

    0

    8.

     

     

    Shared Voting Power

     

    6,396,283  

    9.

     

     

    Sole Dispositive Power

     

    0  

    10.

     

     

    Shared Dispositive Power

     

    6,396,283  

     

     

     

    11.

     

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,396,283  

     

     

     

    12.

     

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨ 

     

     

     

    13.

     

     

    Percent of Class Represented by Amount in Row (11)

     

    4.4%* 

     

     

     

    14.

     

     

    Type of Reporting Person (See Instructions)

     

    CO

             

    * Based on 144,617,762 shares outstanding as of February 14, 2024, as reported in the Issuer’s Report on Form 10-K for the period ended December 31, 2023 filed with the Securities and Exchange Commission on February 15, 2024.

     

    2

     

     

    CUSIP No. 05156V102

     

     

     

     

    1.

     

     

    Name of Reporting Person
    I.R.S. Identification No. of above person (entities only) (voluntary)

     

    ILJIN Semiconductor Co., Ltd.

     

     

     

    2.

     

     

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) x

     

     

     

    3.

     

     

    SEC Use Only

     

     

     

     

     

    4.

     

     

    Source of Funds (See Instructions)

     
    Not Applicable
     

     

     

     

    5.

     

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)  ¨

     

     

     

     

     

    6.

     

     

    Citizenship or Place of Organization

     
    South Korea
     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    7.

     

     

    Sole Voting Power

     

    0

    8.

     

     

    Shared Voting Power

     

    0

    9.

     

     

    Sole Dispositive Power

     

    0  

    10.

     

     

    Shared Dispositive Power

     

    0

     

     

     

    11.

     

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0

     

     

     

    12.

     

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨ 

     

     

     

    13.

     

     

    Percent of Class Represented by Amount in Row (11)

     

    0 

     

     

     

    14.

     

     

    Type of Reporting Person (See Instructions)

     

    CO

             

    3

     

     

    CUSIP No. 05156V102

     

     

     

     

    1.

     

     

    Name of Reporting Person
    I.R.S. Identification No. of above person (entities only) (voluntary)

     

    ILJIN Steel Co., Ltd. 

     

     

     

    2.

     

     

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) x

     

     

     

    3.

     

     

    SEC Use Only

     

     

     

     

     

    4.

     

     

    Source of Funds (See Instructions)

     
    Not Applicable
     

     

     

     

    5.

     

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)  ¨

     

     

     

     

     

    6.

     

     

    Citizenship or Place of Organization

     
    South Korea
     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    7.

     

     

    Sole Voting Power

     

    0

    8.

     

     

    Shared Voting Power

     

    1,123,608

    9.

     

     

    Sole Dispositive Power

     

    0  

    10.

     

     

    Shared Dispositive Power

     

    1,123,608

     

     

     

    11.

     

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,123,608

     

     

     

    12.

     

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨ 

     

     

     

    13.

     

     

    Percent of Class Represented by Amount in Row (11)

     

    0.8%* 

     

     

     

    14.

     

     

    Type of Reporting Person (See Instructions)

     

    CO

             

    * Based on 144,617,762 shares outstanding as of February 14, 2024, as reported in the Issuer’s Report on Form 10-K for the period ended December 31, 2023 filed with the Securities and Exchange Commission on February 15, 2024.

     

    4

     

     

    CUSIP No. 05156V102

     

     

     

     

    1.

     

     

    Name of Reporting Person
    I.R.S. Identification No. of above person (entities only) (voluntary)

     

    ILJIN GLS Co., Ltd.*

     

     

     

    2.

     

     

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) x

     

     

     

    3.

     

     

    SEC Use Only

     

     

     

     

     

    4.

     

     

    Source of Funds (See Instructions)

     
    Not Applicable
     

     

     

     

    5.

     

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)  ¨

     

     

     

     

     

    6.

     

     

    Citizenship or Place of Organization

     
    South Korea
     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    7.

     

     

    Sole Voting Power

     

    0

    8.

     

     

    Shared Voting Power

     

    6,396,283 **

    9.

     

     

    Sole Dispositive Power

     

    0  

    10.

     

     

    Shared Dispositive Power

     

    6,396,283 **

     

     

     

    11.

     

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,396,283 **

     

     

     

    12.

     

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨ 

     

     

     

    13.

     

     

    Percent of Class Represented by Amount in Row (11)

     

    4.4% ***

     

     

     

    14.

     

     

    Type of Reporting Person (See Instructions)

     

    CO

             

    * Formerly known as ILJIN C&S Co., Ltd.

    ** Represents Common Shares held by ILJIN SNT.

    *** Based on 144,617,762 shares outstanding as of February 14, 2024, as reported in the Issuer’s Report on Form 10-K for the period ended December 31, 2023 filed with the Securities and Exchange Commission on February 15, 2024.

     

    5

     

     

    CUSIP No. 05156V102

     

     

     

     

    1.

     

     

    Name of Reporting Person
    I.R.S. Identification No. of above person (entities only) (voluntary)

     

    Sae Kyoung Huh 

     

     

     

    2.

     

     

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) x

     

     

     

    3.

     

     

    SEC Use Only

     

     

     

     

     

    4.

     

     

    Source of Funds (See Instructions)

     
    Not Applicable
     

     

     

     

    5.

     

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)  ¨

     

     

     

     

     

    6.

     

     

    Citizenship or Place of Organization

     
    South Korea
     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    7.

     

     

    Sole Voting Power

     

    722,740 

    8.

     

     

    Shared Voting Power

     

    0

    9.

     

     

    Sole Dispositive Power

     

    722,740 

    10.

     

     

    Shared Dispositive Power

     

    0

     

     

     

    11.

     

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    722,740

     

     

     

    12.

     

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨ 

     

     

     

    13.

     

     

    Percent of Class Represented by Amount in Row (11)

     

    0.5%* 

     

     

     

    14.

     

     

    Type of Reporting Person (See Instructions)

     

    IN

             

     * Based on 144,617,762 shares outstanding as of February 14, 2024, as reported in the Issuer’s Report on Form 10-K for the period ended December 31, 2023 filed with the Securities and Exchange Commission on February 15, 2024.

     

    6

     

     

    CUSIP No. 05156V102

     

     

     

     

    1.

     

     

    Name of Reporting Person
    I.R.S. Identification No. of above person (entities only) (voluntary)

     

    Seoung Eun Huh 

     

     

     

    2.

     

     

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) x

     

     

     

    3.

     

     

    SEC Use Only

     

     

     

     

     

    4.

     

     

    Source of Funds (See Instructions)

     
    Not Applicable
     

     

     

     

    5.

     

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)  ¨

     

     

     

     

     

    6.

     

     

    Citizenship or Place of Organization

     
    South Korea
     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    7.

     

     

    Sole Voting Power

     

    614,333

    8.

     

     

    Shared Voting Power

     

    0

    9.

     

     

    Sole Dispositive Power

     

    614,333

    10.

     

     

    Shared Dispositive Power

     

    0

     

     

     

    11.

     

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    614,333

     

     

     

    12.

     

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨ 

     

     

     

    13.

     

     

    Percent of Class Represented by Amount in Row (11)

     

    0.4%* 

     

     

     

    14.

     

     

    Type of Reporting Person (See Instructions)

     

    IN

             

     * Based on 144,617,762 shares outstanding as of February 14, 2024, as reported in the Issuer’s Report on Form 10-K for the period ended December 31, 2023 filed with the Securities and Exchange Commission on February 15, 2024.

     

    7

     

     

    CUSIP No. 05156V102

     

     

     

     

    1.

     

     

    Name of Reporting Person
    I.R.S. Identification No. of above person (entities only) (voluntary)

     

    Chin Kyu Huh 

     

     

     

    2.

     

     

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) x

     

     

     

    3.

     

     

    SEC Use Only

     

     

     

     

     

    4.

     

     

    Source of Funds (See Instructions)

     
    Not Applicable, PF
     

     

     

     

    5.

     

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)  ¨

     

     

     

     

     

    6.

     

     

    Citizenship or Place of Organization

     
    South Korea
     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    7.

     

     

    Sole Voting Power

     

    0

    8.

     

     

    Shared Voting Power

     

    7,539,891 *

    9.

     

     

    Sole Dispositive Power

     

    0

    10.

     

     

    Shared Dispositive Power

     

    7,539,891 *

     

     

     

    11.

     

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    7,539,891 *

     

     

     

    12.

     

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨ 

     

     

     

    13.

     

     

    Percent of Class Represented by Amount in Row (11)

     

    5.2% ** 

     

     

     

    14.

     

     

    Type of Reporting Person (See Instructions)

     

    IN

             

    * Consists of (i) 6,396,283 Common Shares held by ILJIN SNT and (ii) 1,123,608 Common Shares held by ILJIN Steel.

    ** Based on 144,617,762 shares outstanding as of February 14, 2024, as reported in the Issuer’s Report on Form 10-K for the period ended December 31, 2023 filed with the Securities and Exchange Commission on February 15, 2024.

     

    8

     

     

    CUSIP No. 05156V102

     

    AMENDMENT NO. 15 TO SCHEDULE 13D

     

    Reference is hereby made to the statement on Schedule 13D filed with the Securities and Exchange Commission by the Reporting Persons with respect to the Common Shares on April 8, 2019, Amendment No. 1 thereto filed on June 4, 2019, Amendment No. 2 thereto filed on November 13, 2019, Amendment No. 3 thereto filed on December 6, 2019, Amendment No. 4 thereto filed on December 9, 2019, Amendment No. 5 thereto filed on December 10, 2019, Amendment No. 6 thereto filed on December 18, 2019, Amendment No. 7 thereto filed on July 23, 2020, Amendment No. 8 thereto filed on October 9, 2020, Amendment No. 9 thereto filed on January 26, 2021, Amendment No. 10 thereto filed on January 27, 2021, Amendment No. 11 thereto filed on March 3, 2022, Amendment No. 12 thereto filed on January 6, 2023, Amendment No. 13 thereto filed on January 20, 2023 and Amendment No. 14 thereto filed on May 10, 2023 (as so amended, the “Schedule 13D”). Terms defined in the Schedule 13D are used herein as so defined.

     

    The following item of the Schedule 13D is hereby amended as follows:

     

    Item 4. Purpose of Transaction

     

    Item 4 of the Schedule 13D is hereby amended and supplemented to include the following:

     

    On March 20, 2024, Iljin SNT Co., Ltd. (“ILJIN”) delivered a letter to the Issuer’s management team and Board of Directors to express its concerns regarding the composition of the Issuer’s management team and the Issuer’s continued poor performance. In the letter, ILJIN urged the Board of Directors to revamp the Company’s management team and to rationalize the Company’s spending.

     

    The foregoing description of the letter does not purport to be complete and is qualified in its entirety by reference to the full text of the letter, which is filed as Exhibit 99.1, and is incorporated herein by reference.

     

    The Reporting Persons do not intend to engage in a control transaction, or any contested solicitation for the election of directors, with respect to the Issuer.

     

    Item 5. Interest in Securities of the Issuer

     

    Paragraphs (a) and (b) of Item 5 of the Schedule 13D are hereby amended and restated to read as follows:

     

    (a)-(b) The information requested by these paragraphs is incorporated herein by reference to the cover pages to this Amendment No. 14 to Schedule 13D.

     

    Item 7. Materials to be Filed as Exhibits

     

    Exhibit 99.1 Letter to Management and Board of Directors, dated March 20, 2024

     

    9

     

     

    CUSIP No. 05156V102

     

    SIGNATURE

     

    After reasonable inquiry and to the best of the knowledge and belief of the undersigned, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated: March 20, 2024 ILJIN SNT CO., LTD.  
       
      By: /s/ Young Hwa Kim  
        Name: Young Hwa Kim   
        Title: Authorized Signatory   
           
      ILJIN SEMICONDUCTOR CO., LTD.  
       
      By: /s/ Young Hwa Kim
        Name: Young Hwa Kim
        Title: Authorized Signatory   
           
      ILJIN STEEL CO., LTD.  
       
      By: /s/ Young Hwa Kim  
        Name: Young Hwa Kim
        Title: Authorized Signatory   
           
      ILJIN GLS CO. LTD.  
       
      By: /s/ Young Hwa Kim  
        Name: Young Hwa Kim 
        Title: Authorized Signatory   
           
      /s/ Chin Kyu Huh  
      Chin Kyu Huh  
       
      /s/ Sae Kyoung Huh  
      Sae Kyoung Huh
       
      /s/ Seoung Eun Huh
      Seoung Eun Huh

     

     

    Get the next $AUPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AUPH

    DatePrice TargetRatingAnalyst
    11/4/2022Outperform → Perform
    Oppenheimer
    5/5/2022$34.00 → $25.00Overweight
    Cantor Fitzgerald
    3/8/2022$30.00 → $22.00Outperform
    SVB Leerink
    3/1/2022$31.00 → $27.00Outperform
    RBC Capital
    2/23/2022$34.00 → $31.00Outperform
    RBC Capital
    12/10/2021$33.00 → $31.00Perform → Outperform
    Oppenheimer
    11/4/2021$32.00 → $33.00Perform
    Oppenheimer
    11/4/2021$35.00 → $40.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AUPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis

      LUPKYNIS Data Presented at LUPUS 2025, the 16th International Congress on SLE, May 21-24 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), today announced that a post-hoc analysis of the 52-week, Phase 3 AURORA 1 study showed that lupus nephritis (LN) patients who received triple immunosuppressive therapy with LUPKYNIS® (voclosporin), mycophenolate mofetil (MMF), and low-dose glucocorticoids achieved lower proteinuria targets at substantially higher rates compared to patients in the control group who received mycophenolate mofetil (MMF) and low-dose glucocorticoids alone. The analysis assessed the achievement of urine protein creatine ratio (UPCR) targets of ≤0.4 g/g, ≤

      5/22/25 6:00:00 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

      Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Results Total Revenue: For the three months ended March 31, 2025, total revenue was $62.5 million, up 24% from $50.3 million in the same period of 2024. Net Product Sales: For the three months ended March 31, 2025, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $60.0 million, up 25% from $48.1 million in the same period of 2024. License, Collaboration and Royalty Revenue: For the three months ended March 31, 2025, license, collaboration and royalty

      5/12/25 6:00:00 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025

      Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release first quarter 2025 financial and operational results before markets open on May 12, 2025. Aurinia's management team will host a conference call and webcast at 8:30 AM ET that day to review these results and provide a general business update. The link to the audio webcast is available here. To join the conference call, please dial 877-407-9170 / +1 201-493-6756. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia Pharmaceuticals is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medi

      5/5/25 6:00:00 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AUPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Nova Tina Susan

      4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

      5/16/25 5:06:05 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Johnson Craig A

      4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

      5/16/25 5:05:19 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Goetz Kathleen

      4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

      5/16/25 5:04:45 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AUPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aurinia Pharmaceuticals Inc

      SC 13G/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)

      11/14/24 4:47:34 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Aurinia Pharmaceuticals Inc

      SC 13D - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)

      9/12/24 4:10:26 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Aurinia Pharmaceuticals Inc (Amendment)

      SC 13D/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)

      3/20/24 5:23:55 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AUPH
    Financials

    Live finance-specific insights

    See more
    • Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

      Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Results Total Revenue: For the three months ended March 31, 2025, total revenue was $62.5 million, up 24% from $50.3 million in the same period of 2024. Net Product Sales: For the three months ended March 31, 2025, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $60.0 million, up 25% from $48.1 million in the same period of 2024. License, Collaboration and Royalty Revenue: For the three months ended March 31, 2025, license, collaboration and royalty

      5/12/25 6:00:00 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025

      Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release first quarter 2025 financial and operational results before markets open on May 12, 2025. Aurinia's management team will host a conference call and webcast at 8:30 AM ET that day to review these results and provide a general business update. The link to the audio webcast is available here. To join the conference call, please dial 877-407-9170 / +1 201-493-6756. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia Pharmaceuticals is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medi

      5/5/25 6:00:00 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

      Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three and twelve months ended December 31, 2024 and provided an update on recent corporate progress. Fourth Quarter 2024 Financial Results Total Revenue: For the three months ended December 31, 2024, total revenue was $59.9 million, up 33% from $45.1 million in the same period of 2023. – Net Product Sales: For the three months ended December 31, 2024, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $57.6 million, up 36% from $42.3 million in the same period of 2023. – License, Collaboration and Royalty Revenue

      2/27/25 6:00:00 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AUPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aurinia Pharma downgraded by Oppenheimer

      Oppenheimer downgraded Aurinia Pharma from Outperform to Perform

      11/4/22 7:15:31 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald resumed coverage on Aurinia Pharma with a new price target

      Cantor Fitzgerald resumed coverage of Aurinia Pharma with a rating of Overweight and set a new price target of $25.00 from $34.00 previously

      5/5/22 9:08:41 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Aurinia Pharmaceuticals with a new price target

      SVB Leerink reiterated coverage of Aurinia Pharmaceuticals with a rating of Outperform and set a new price target of $22.00 from $30.00 previously

      3/8/22 4:46:01 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AUPH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $AUPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $AUPH
    Leadership Updates

    Live Leadership Updates

    See more

    $AUPH
    SEC Filings

    See more
    • FDA Approval for LUPKYNIS

      Submission status for AURINIA PHARMACEUTICALS, INC.'s drug LUPKYNIS (ORIG-1) with active ingredient VOCLOSPORIN has changed to 'Approval' on 01/22/2021. Application Category: NDA, Application Number: 213716, Application Classification: Type 1 - New Molecular Entity

      1/25/21 11:31:10 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Tang Kevin bought $12,713,126 worth of shares (1,600,000 units at $7.95) (SEC Form 4)

      4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

      3/4/25 5:03:02 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Tang Kevin bought $10,822,000 worth of shares (1,200,000 units at $9.02) (SEC Form 4)

      4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

      12/9/24 4:52:50 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

      Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it has appointed Craig Johnson to its Board of Directors (the Board) to support its next phase of growth. Mr. Johnson has more than 30 years of experience serving in senior financial management roles and governing companies in the biotechnology industry. He previously served as a director of Ardea Biosciences, Inc., Adamis Pharmaceuticals Corporation, Decipher Biosciences, Inc., La Jolla Pharmaceutical Company, Odonate Therapeutics, Inc. and Mirati Therapeutics, Inc. He currently serves as a director of Heron Therapeutics, Inc. His biography can be found here. The Company also announced that Dr. Robert

      11/7/24 6:10:00 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aurinia Announces 2024 Annual General Meeting Results

      Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced voting results for its 2024 annual general meeting (the Meeting) of shareholders held on June 14, 2024. Shareholders re-elected five of nine incumbent directors to the Board of Directors (the Board). The four directors, while elected under applicable corporate law, who received less than majority support are Peter Greenleaf, Director, President and CEO; Daniel G. Billen, Ph.D., Director, Chair of the Board, Chair of the Compensation Committee, and Member of the Audit Committee; R. Hector MacKay-Dunn, J.D., K.C., Director, Chair of the Governance & Nomination Committee and Member of the Compensation Committ

      6/14/24 12:16:00 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital

      Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company") today announced that its Board of Directors ("the Board") has appointed Dr. Robert T. Foster to the Board. MKT Capital Ltd. (together with its affiliates, "MKT Capital") submitted Dr. Foster as a candidate and worked collaboratively with Aurinia to name him to the Board. In connection with Dr. Foster's appointment, MKT Capital has entered into a cooperation agreement with Aurinia. A complete copy of the cooperation agreement will be available on our profiles on EDGAR and SEDAR. "We are appreciative of MKT's constructive collaboration efforts. Dr. Foster brings talents which can help strengthen the Board even further

      9/21/23 6:00:00 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Aurinia Pharmaceuticals Inc

      S-8 - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)

      5/16/25 5:01:56 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aurinia Pharmaceuticals Inc filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)

      5/15/25 4:06:13 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Aurinia Pharmaceuticals Inc

      10-Q - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)

      5/12/25 6:05:39 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care